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Patients with severe pre-eclampsia were randomised to
receive magnesium sulphate according to an
intramuscular (IM) (N =9) or an intravenous (IV) (N =8)
regimen. The IM regimen consisted of a loading dose of
14 g (4 g IV and 10 g IM) followed by 5 g 4-hourly. Patients
given the IV regimen received a 6 g IV loading dose
followed by a maintenance infusion of 2 g/h. Clinical
outcome, laboratory parameters and serum magnesium
levels were recorded for both groups.
There were no significant differences between groups
with regard to clinical outcome of either mother or child.
Similar average serum magnesium concentrations were
produced by the regimens the only significant difference
was that fluctuations in magnesium levels were greater
with the IM than the IV regimen. None of the patients had
seizures despite levels mostly below 2 mmol/l.
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Magnesium sulphate (MgSO,) is the anticonvulsant most
widely used in the USA and South Africa for the
management of severe pre-eclampsia. It is given
parenterally, usually according to one of two popular
regimens: the intramuscular (IM) regimen introduced by
Pritchard' and a continuous intravenous (IV) infusion
described by Zuspan! Sibai et a/.3 have reported that lower
serum magnesium values are achieved with Zuspan's
regimen (maintenance dose 1g/h) than with Pritchard's
regimen. Given that Sibai et al.' had previously found that 8
of 9 convulsing patients had low levels of serum magnesium
after receiving Zuspan's regimen, they concluded that an IV
maintenance dose of 1 g/h was insufficient to prevent the
occurrence of seizures in some pre-eclamptic patients. They
thus recommend an IV maintenance dose of 2 g/h.3
The purpose of this prospective study was to compare the
clinical outcome as well as the magnesium levels obtained
in the treatment of severe pre-eclampsia with the IM
regimen of Pritchard and an IV regimen with maintenance
doses of 2 g/h.
Subjects and methods
Seventeen women with severe pre-eclampsia and imminent
eclampsia were studied at King Edward VIII (KEH) Hospital
in Durban. This hospital is a tertiary referral centre for the
coastal region of Natal and serves an indigent population
from poor socio-economic conditions. Delivery of 14 000
high-risk patients is conducted each year and 18% of all
obstetric admissions have some degree of hypertension.
Patients eligible for the trial had proteinuria of at least 1+
assessed by a semiquantitative 'dipstick' method (Ames)
and diastolic blood pressures of 110 mmHg or more which
did not settle during a 4-hour observation period. Patients
with hypertension and proteinuria who had additional
symptoms or signs such as persistent headache, visual
disturbances, epigastric pain, increased patellar reflexes and
clonus, were considered to have impending eclampsia - 2
of the 8 women in the IV group and 4 of the 9 women in the
IM group.
After Ethics Committee approval was received, patients
were randomly allocated to receive either IM or IV MgSO,.
Those receiving the IM regimen (N = 9) were given 4 9
MgSO, in 200 ml normal saline as an infusion over 15
minutes and simultaneously given 5 9 MgSO, IM in each
buttock. Thereafter, every 4 hours an additional 5 g MgSO,
were given in alternate buttocks.
Eight patients received continuous IV MgS04. A loading
dose of 6 g in 200 ml normal saline was infused over 15
minutes, followed immediately by a maintenance dose of
2 g/dl/h given via a controlled infusion pump.
In all patients the patellar reflexes and respiratory rate
were noted every 4 hours. When either was suppressed, or
when the urine output was less than 30 ml/h over the
preceding 4 hours, MgSO, was discontinued. MgSO, was
discontinued after 24 hours of therapy, providing delivery
had occurred.
Obstetric management continued according to a standard
protocol previously described.5 If the diastolic blood
pressure reached 115 mmHg, then 6,25 mg dihydralazine in
10 ml normal saline was infused over a period of at least 5
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Table 11. Further.details of patients in the IM and IV groups
• One patient had twins.
t This consisted of methyldopa and dihydralazine, except in the case of 1 patient in the
IV group who also received dexamethasone and phenobarbitone.
:j: Dihydralazine.
Various other details for the two groups can be seen in
Table 11. None of the patients had seizures. Only 1 patient
(in the IV group) had clinical signs of magnesium tOXicity
(oliguria and decreased patella reflexes) which necessitated
the cessation of MgSO. therapy after 7 hours. The serum
magnesium level in this patient at 7 hours was 1,97 mmol/I
(baseline serum magnesium level 0,76 mmc;>I/I). In another
patient (mentioned above) MgSO. was stopped because of
renal failure. There were no differences between groups
with regard to mode of delivery or fetal outcome. Seven out
of 8 women in the IV group, as opposed to 2 out of 9 in the
IM group, had antenatal medication. However, in the
absence of pre-pregnancy or post-delivery blood pressure
measurements, it was assumed that all patients had
proteinuric pregnancy-induced hypertension or essential
hypertension with superimposed pre-eclampsia. Figs 1 and
2 show that similar average serum magnesium
concentrations were produced by the two regimens.
Table I. Maternal and neonatal data (means ±SD)
IM MgSO. IV MgSO.
Group (N=9) (N=8)
Patient details
Age (yrs) 21,4 ± 4,5 23,6 ± 6,8
Weight (kg) 73,8 ± 10,1 73,5 ± 4,8
Systolic BP (mmHg) 169,0 ± 13,6 163,0 ± 13,9
Diastolic BP (mmHg) 114,0 ± 7,3 113,0 ± 4,6
Serum creatinine (IJmol/l) 59,3 ± 10,7 87,4 ± 60,3
24-h urinary protein (gII) 1,1 ± 1,1 1,0 ± 0,9
(N= 8) (N=7)
Haematocrit (%) 29,2 ± 3,3 31,2± 3,6
Platelet count (x 109/1) 259,0 ± 72,1 207,0 ± 64,8
Delivery time relative to 5,8 ± 4,2 5,3 ± 3,1
start of MgSO. (h)
Serum albumin (gll)
Oh 26,3 ± 3,0 22,0 ± 4,0
11 h 20,0 ± 3,0 18,0 ± 3,0
(N= 8) (N=6)
19 h 20,0 ±4,0 16,0 ± 3,0
(N=7) (N=5)
Serum calcium (mmol/I)
Oh 2,01 ±0,10 1,96 ± 0,10
11 h 1,58 ± 0,20 1,51 ± 0,20
(N=8) (N=6)
19 h 1,66 ± 0,15 1,44 ± 0,15
(N=7) (N=5)
Details of baby
Weight (kg) 2,6 ± 0,9 2,4 ± 0,8
Gestational age (wks) 35,9 ± 3,5 34,6 ± 3,2
Apgar score
1 min 6,0 ± 3,0 6,0 ± 3,0
































minutes. High blood pressure was only lowered after the
correction of hypovolaemia with Ringer's lactate solution.
Hypovolaemia was assessed by central venous pressure
(CVP) which was measured by inserting a central line
through a large vein in the antecubital fossa. The position of
the tip of the CVP catheter was checked by radiological
examination of the chest.
Various maternal investigations were carried out, including
measurement of haematocrit, platelet count, serum
creatinine (on entry), serum albumin and calcium levels and
24-hour urinary protein. Maternal convulsions, if they
occurred, were noted. Details of delivery, gestational age
and fetal weight, and Apgar scores were also recorded.
Serum magnesium levels were measured at baseline and
repeated every 30 minutes for the first 3 hours after the
loading dose. They were subsequently measured at 5, 7, 9,
11, 15 and 19 hours. Blood was taken through the CVP line
with allowance made for the dead space. Samples were
centrifuged at once and serum was analysed the following
day by the routine hospital laboratory, using a dye-binding
procedure with Calmagite (Beckman Sychron CX5).
Serum magnesium levels versus time were plotted for all
patients and the following values were recorded for each:
c~ 1 - the first peak level recorded; ~, - the time of this
peak; Cmax 2 - the highest overall peak in the first 12 hours
(in some cases equal to cmax ,); ~ 2 - the time of this peak
(in some cases equal to~ ,); Cmin - the lowest level
recorded in the first 12 hours; trun - the time of this trough;
and 8Cp = Cmax 2 - Cmin - the maximum fluctuation in serum
levels during the first 12 hours.
All these values were compared between patients from
the IM and IV groups in an attempt to quantitate whether or
not any differences resulted from the two regimens.
Differences between the IM and IV groups were assessed
by means of the unpaired Student's Hest. A P-value of 0,05
or less was considered to represent a statistically significant
difference between groups.
Changes in both serum albumin and serum calcium levels
from 0 - 11 hours and 0 - 19 hours within both the IM and IV
groups were assessed by the paired Student's Hest. The
Bonferroni adjustment was applied and a P-value of 0,025
or less was considered significant.
Results
Demographic details, blood pressure values and results of
investigations for the mothers, as well as the fetal weights,
gestational ages and Apgar scores of the babies, are
presented in Table I. The only statistically significant
differences between the IM and the IV groups were in the
baseline serum albumin levels (P = 0,034) and the serum
calcium levels at 19 hours (P = 0,032). The serum creatinine
values in both groups were similar, except for 1 patient in
the IV group with a value of 229 ~mol/l. Dosing of this
patient was stopped after 3 hours. Serum albumin levels fell
significantly between 0 and 11 hours in both the IM (P =
0,004) and IV groups (P = 0,0024) as well as between 0 and
19 hours (P =0,008 IM, P =0,0075 IV). There was also a
significant fall in serum calcium levels between 0 and 11
hours (P = 0,004 IM; P = 0,0021 IV) and between 0 and 19
hours (P =0,0004 IM; P =0,0025 IV).
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Number of sample points between 0 and 19 hours: 8, 8, 8, 8, 8, 8, 8, 7, 7, 7,5, 3 and 4.
Number of sample points between 0 and 19 hours: 9, 9, 9, 7, 9, 8, 9, 8, 8, 7, 8, 5 and 4.
by the two regimens or the times at which these values were
reached. However comparison of values of L'.Cp (the highest
peak minus the trough) revealed that fluctuations in serum
magnesium levels were significantly greater with the IM than
with the IV regimen (P = 0,026).
Discussion
This study, which set out to compare the IM MgS04 regimen
of Pritchard' with an IV regimen3 using a maintainance dose
of 2 g/h in patients with severe pre-eclampsia, revealed very
little difference between the groups. The clinical outcome of
the patients and their babies was similar and none of the
patients had convulsions.
The fact that serum calcium levels fell significantly during
magnesium treatment was consistent with the findings of
the other workers who have shown a similar reciprocal
relationship between the ions.3 In the present study,
however, serum calcium levels were significantly lower in the
IV group after 19 hours than in the IM group.
The average maintenance serum magnesium levels
produced by the IM regimen (total dose of 24 g up to 12
hours) were only very slightly lower than those produced by
the IV regimen (total dose of 30 g over 12 hours). The only
statistically significant difference between regimens, notably
the fluctuation in levels, was predictable in that the
difference between maximum and minimum serum levels
could be expected to be greater with an IM than an IV
regimen.
Sibai et al. 3 have·compared an IV regimen using a
maintenance infusion of 2 g/h with an IM regimen similar to
Pritchard's in 15 patients with severe pre-eclampsia. They
also showed the regimens to be clinically equivalent in the
prevention of seizures. However, they reported greater
differences between serum magnesium levels than were
noted in the present study. They found that higher levels
were produced by the IM regimen, particularly in the first 3
hours.
Comparison between Sibai et a/.'s3 and the present study
in respect of levels produced by the IV regimens revealed
very similar mean maintenance levelsof approximately 1,68
- 2,10 mmol/I and 1,7 - 1,9 mmol/I respectively. It was not
possible to compare peaks after the loading dose (which
was only 4 g in that study) as sampling in the present study
only began at 30 minutes.
In contrast to the similarity in IV findings, the average
maintenance levels achieved with our IM regimen (1,5 - 1,8
mmol/l) were lower than those produced by Sibai et al. 'S3 IM
regimen (1,9 - 2,7 mmol/I). Pritchard6 has also reported
higher levels (2 - 3,5 mmol/I) than ours, with an identical IM
regimen.
Neither Sibai et al. 3 nor Pritchard6 provide baseline serum
magnesium levels for their patients. In the present study
baseline levels were at the lower end of normal and perhaps
this could account for the fact that similar regimens to those
used by other workers resulted in lower levels.
This explanation would, however, not be consistent with
the fact that levels produced by the IV regimens in Sibai
et al.'s3 and the present study were so similar. Dommisse'



































Fig. 2. Mean :I: SO serum magnesium levels for patients on the IV
regimen.
Table Ill. Magnesium doses and maximum and minimum serum






There were no statistically significant differences between
the maximum and minimum serum concentrations produced
The doses of MgS04, the mean values of the maximum
and minimum serum concentrations and the maximal
fluctuations in serum concentrations are presented in
Table Ill.







Total dose up to 12 hours (g)









c",.., - the first maximum level recorded, t",.., - the time of the first maximum level,
c_ - the lowest level recorded in the first 12 hours, t".., - the time of this trough, !1 c,
- the highest peak in the 1st 12 hours minus the lowest trough, Le. the maximal
fluctuation in levels in the 1st 12 hours.
I
L
SAMJ Volume 84 No.9 September 1994
The difference in the levels produced by the IM regimens of
Sibai et a/. 3 and the present study is particularly marked
between 0,5 and 2 hours during which time identical amounts
of MgS04 - a loading dose of 14 g (4 g IV and 10 g IM) -
would have been received. Sibai et al. 'S3 mean levels were
approximately 2,8 mmol/I at 0,5 hours and approximately
2,7 mmol/I at 2 hours compared with mean levels in the
present study of 1,9 mmol/I and 1,7 mmol/I respectively.
Sibai et al. 3 suggest that their high levels with the IM regimen
in the first 3 hours may be due to the high loading dose, and
this does appear to be a logical explanation. Although similar
high I~vels were probably produced in the present study in
the first 30 minutes (and were not recorded as levels were not
measured at this time) the reason why our levels fell so much
quicker and eventually to lower levels than in Sibai et al. 'S3
study is unclear.
The optimal serum magnesium levels required for control
of eclamptic seizures are unknown. Pritchard6 indicated
that the levels of 2 - 3,5 mmol/I produced by his regimen
were satisfactory for preventing convulsions in patients
with severe pre-eclampsia, and Hall" suggested levels of
3 - 4 mmol/I for optimal control. Sibai et a/. 4 also noted in a
series of 13 patients who had fits while receiving magnesium
that 11 had levels below 2 mmoVI.
On the other hand, Cruikshank et al. 9 suggested that
therapeutic levels of magnesium may be lower than those
recommended by Pritchard. Flowers et al. '°suggest that
levels of 1,24 - 2,47 mmol/I are usually satisfactory.
The findings of the present study, in which none of the
patients had fits despite levels which were mostly below
2 mmol/I, support the contention that optimal levels may
be lower than generally believed. However a group of only
17 patients is probably too small to make such an
assessment accurately.
In summary, the present study has shown that seizures
were controlled in our severely pre-eclamptic patients at
serum levels lower than those generally considered
then:~peutic. There was little to choose between the IM and
IV regimens in that they provided similar levels and a
comJjlarable clinical outcome. While the IM regimen has the
disadvantage of painful injections, it has the advantage of
greater convenience and safety. In our setting, pumps for IV
infusion are not readily available and, in addition, the nursing
staff may be too busy to provide the continuous monitoring
required. The IM route, where a dose will only be given once
reflexes, respiration and urine output have been checked, is
likely to be safer.
This study was supported by the Pregnancy Hypertension
Research Unit of the South African Medical Research
Council.
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July 1990 - June 1991
J. Byarugaba, D. Kielkowski
This is a retrospective analysis of 5 600 deaths
registered in Soweto from July 1990 to June 1991. The
impact of trauma and violence on the overall mortality
pattern was assessed. The majority of deaths occurred in
people under the age of 50 years and more men died than
women. In 40% of male deaths, the cause was stated as
'ill-defined' or 'unknown'; this was the case in an even
higher percentage of female deaths (50,5%). Trauma or
violence accounted for 28,5% of all deaths. The gender
difference was particularly visible in the trauma category,
viz. 89,5% and 10,5% in men and women respectively.
Young men (20 - 29 years) were particularly affected by
trauma and violence-related deaths (38,5%). The major
types of injuries inflicted were gunshot wounds (33%),
unspecified multiple injuries (32%) and stab wounds
(27%). Motor vehicle accidents accounted for only 8% of
deaths. The urgent need for intervention programmes to
prevent unnecessary loss of life, targeted especially at
young adults and children, is highlighted.
S Afr Med J 1994; 84: 610-614.
Soweto (an acronym for South-Western Townships) was
established in 1939 and is. the largest black township in
South Africa. It covers an area of approximately 660
hectares and is situated 15 km south-west of Johannesburg.
Soweto's historical, geographical and demographic
characteristics are probably similar to other rapidly
expanding urban and peri-urban townships. Such rapid
urbanisation has resulted in many public health problems.
Department of Health, Soweto City Council and Epidemiology Unit,
National Centre for Occupational Health and Department of
Community Health, University of the Witwatersrand, Johannesburg
J. Byarugaba, M.B. CH.B., M.P.H.
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